Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
N Engl J Med ; 382(10): 929-936, 2020 03 05.
Artículo en Inglés | MEDLINE | ID: mdl-32004427

RESUMEN

An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV infection confirmed in the United States and describe the identification, diagnosis, clinical course, and management of the case, including the patient's initial mild symptoms at presentation with progression to pneumonia on day 9 of illness. This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.


Asunto(s)
Betacoronavirus/genética , Infecciones por Coronavirus , Pulmón/diagnóstico por imagen , Neumonía Viral , Adulto , Betacoronavirus/aislamiento & purificación , Análisis Químico de la Sangre , COVID-19 , Prueba de COVID-19 , China , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/transmisión , Progresión de la Enfermedad , Genoma Viral , Humanos , Pulmón/patología , Masculino , Neumonía Viral/diagnóstico , Neumonía Viral/terapia , Neumonía Viral/transmisión , Radiografía Torácica , SARS-CoV-2 , Análisis de Secuencia de ADN , Viaje , Estados Unidos
2.
Am J Public Health ; 111(5): 867-875, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33734847

RESUMEN

Laboratory diagnostics play an essential role in pandemic preparedness. In January 2020, the first US case of COVID-19 was confirmed in Washington State. At the same time, the Washington State Public Health Laboratory (WA PHL) was in the process of building upon and initiating innovative preparedness activities to strengthen laboratory testing capabilities, operations, and logistics. The response efforts of WA PHL, in conjunction with the Centers for Disease Control and Prevention, to the COVID-19 outbreak in Washington are described herein-from the initial detection of severe acute respiratory syndrome coronavirus 2 through the subsequent 2 months.Factors that contributed to an effective laboratory response are described, including preparing early to establish testing capacity, instituting dynamic workforce solutions, advancing information management systems, refining laboratory operations, and leveraging laboratory partnerships. We also report on the challenges faced, successful steps taken, and lessons learned by WA PHL to respond to COVID-19.The actions taken by WA PHL to mount an effective public health response may be useful for US laboratories as they continue to respond to the COVID-19 pandemic and may help inform current and future laboratory pandemic preparedness activities.


Asunto(s)
Prueba de COVID-19 , COVID-19 , Laboratorios , Objetivos Organizacionales , Desarrollo de Programa , Salud Pública , COVID-19/epidemiología , COVID-19/prevención & control , Centers for Disease Control and Prevention, U.S. , Humanos , Sistemas de Información , Estados Unidos , Washingtón/epidemiología
3.
Emerg Infect Dis ; 26(8): 1671-1678, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32470316

RESUMEN

We describe the contact investigation for an early confirmed case of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the United States. Contacts of the case-patient were identified, actively monitored for symptoms, interviewed for a detailed exposure history, and tested for SARS-CoV-2 infection by real-time reverse transcription PCR (rRT-PCR) and ELISA. Fifty contacts were identified and 38 (76%) were interviewed, of whom 11 (29%) reported unprotected face-to-face interaction with the case-patient. Thirty-seven (74%) had respiratory specimens tested by rRT-PCR, and all tested negative. Twenty-three (46%) had ELISA performed on serum samples collected ≈6 weeks after exposure, and none had detectable antibodies to SARS-CoV-2. Among contacts who were tested, no secondary transmission was identified in this investigation, despite unprotected close interactions with the infectious case-patient.


Asunto(s)
Betacoronavirus/patogenicidad , Trazado de Contacto/estadística & datos numéricos , Infecciones por Coronavirus/epidemiología , Pandemias , Neumonía Viral/epidemiología , Adolescente , Adulto , Anciano , Betacoronavirus/genética , COVID-19 , Prueba de COVID-19 , Niño , Preescolar , Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/diagnóstico , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Neumonía Viral/diagnóstico , Salud Pública/métodos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , SARS-CoV-2 , Viaje , Washingtón/epidemiología
5.
Fed Pract ; 34(8): 18-25, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-29200807

RESUMEN

The U.S. response to the Ebola epidemic resulted in many federal agencies assessing their ability to respond to global threats and improve the efficiency of humanitarian efforts.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA